Literature DB >> 19451059

Resistance mechanisms of tumour cells to EGFR inhibitors.

F Morgillo1, F Cantile, M Fasano, T Troiani, E Martinelli, F Ciardiello.   

Abstract

In spite of the overexpression and efficient inhibition of epidermal growth factor receptor (EGFR), resistance to EGFR inhibitors, monoclonal antibodies and tyrosine kinase inhibitors may occur. Understanding the molecular mechanisms affecting cancer cell sensitivity or resistance to EGFR inhibitors may be of help in deciding on treatment and in new translational studies. This review will focus on the most relevant mechanisms contributing to the acquisition of sensitivity/resistance to EGFR inhibitors.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19451059     DOI： 10.1007/s12094-009-0354-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  56 in total

1.  p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts.

Authors:  J Milanini; F Viñals; J Pouysségur; G Pagès
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

2.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

3.  The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

Authors:  Andrea B Motoyama; Nancy E Hynes; Heidi A Lane
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

4.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Authors:  M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

Review 5.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

6.  Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Authors:  Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

7.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Authors:  Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

8.  Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling.

Authors:  D Graus-Porta; R R Beerli; N E Hynes
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

9.  Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.

Authors:  X Qian; W C Dougall; M E Hellman; M I Greene
Journal:  Oncogene       Date:  1994-05       Impact factor: 9.867

10.  Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").

Authors:  N Magné; J L Fischel; A Dubreuil; P Formento; M-F Poupon; P Laurent-Puig; G Milano
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640
View more
  10 in total

Review 1.  EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?

Authors:  Shailender Singh Kanwar; Jyoti Nautiyal; Adhip P N Majumdar
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

2.  Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

Authors:  Malabika Sen; Sonali Joyce; Mary Panahandeh; Changyou Li; Sufi M Thomas; Jessica Maxwell; Lin Wang; William E Gooding; Daniel E Johnson; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

3.  Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC).

Authors:  Guido Bellezza; Rachele Del Sordo; Renato Colella; Vienna Ludovini; Mark Ragusa; Fortunato Bianconi; Ivana Ferri; Filippo Borri; Rita Chiari; Francesco Puma; Lucio Crinò; Angelo Sidoni
Journal:  Virchows Arch       Date:  2013-09-07       Impact factor: 4.064

Review 4.  Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.

Authors:  Woo-Jeong Jeong; Pu-Hyeon Cha; Kang-Yell Choi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling.

Authors:  Kwan-Young Jung; Ramin Samadani; Jay Chauhan; Kerrick Nevels; Jeremy L Yap; Jun Zhang; Shilpa Worlikar; Maryanna E Lanning; Lijia Chen; Mary Ensey; Sagar Shukla; Rosene Salmo; Geoffrey Heinzl; Caryn Gordon; Troy Dukes; Alexander D MacKerell; Paul Shapiro; Steven Fletcher
Journal:  Org Biomol Chem       Date:  2013-06-14       Impact factor: 3.876

6.  Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.

Authors:  Christopher W Chiu; Hiroaki Nozawa; Douglas Hanahan
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

7.  A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.

Authors:  Carla Lucia Esposito; Diana Passaro; Immacolata Longobardo; Gerolama Condorelli; Pina Marotta; Andrea Affuso; Vittorio de Franciscis; Laura Cerchia
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

8.  Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.

Authors:  Nikolaos Ioannou; Alan M Seddon; Angus Dalgleish; David Mackintosh; Flavio Solca; Helmout Modjtahedi
Journal:  Int J Oncol       Date:  2016-01-05       Impact factor: 5.650

9.  Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models.

Authors:  Emma C Martin; Leon Aarons; James W T Yates
Journal:  Cancer Chemother Pharmacol       Date:  2018-07-27       Impact factor: 3.333

10.  Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.

Authors:  Giuliana Cavalloni; Caterina Peraldo-Neia; Chiara Varamo; Giovanna Chiorino; Francesco Sassi; Massimo Aglietta; Francesco Leone
Journal:  Oncotarget       Date:  2016-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.